Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney Disease
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
AFMMU
Xi'an, China
Start Date
February 1, 2024
Primary Completion Date
August 1, 2025
Completion Date
August 1, 2028
Last Updated
May 6, 2024
208
ESTIMATED participants
Prednisolone
DRUG
Prednisolone plus Cyclophosphamide
DRUG
Lead Sponsor
Air Force Military Medical University, China
NCT03841448
NCT04020328
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions